<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1641">
  <stage>Registered</stage>
  <submitdate>2/08/2007</submitdate>
  <approvaldate>2/08/2007</approvaldate>
  <nctid>NCT00511459</nctid>
  <trial_identification>
    <studytitle>Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients</studytitle>
    <scientifictitle>A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20060341</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Locally Recurrent and Metastatic Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 386 Placebo
Treatment: drugs - AMG 386
Treatment: drugs - Bevacizumab
Treatment: drugs - AMG 386
Treatment: drugs - AMG 386
Treatment: drugs - Paclitaxel

Experimental: A - Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW

Experimental: D - Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10 mg/kg IV QW

Experimental: B - Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW

Active Comparator: C - Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW


Treatment: drugs: AMG 386 Placebo
AMG 386 Placebo [blinded]

Treatment: drugs: AMG 386
AMG 386 3mg/kg IV QW [blinded]

Treatment: drugs: Bevacizumab
Bevacizumab 10mg/kg IV Q2W

Treatment: drugs: AMG 386
AMG 386 10mg/kg IV QW [Open-Label]

Treatment: drugs: AMG 386
AMG 386 10mg/kg IV QW [blinded]

Treatment: drugs: Paclitaxel
Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (PFS)</outcome>
      <timepoint>3 YEARS</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response (OR)</outcome>
      <timepoint>3 YEARS</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DOR)</outcome>
      <timepoint>3 YEARS</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to response</outcome>
      <timepoint>3 YEARS</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>3 YEARS</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to progression (TTP)</outcome>
      <timepoint>3 YEARS</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of AEs and significant laboratory changes</outcome>
      <timepoint>3 YEARS</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AMG 386 Pharmakokinetic parameters</outcome>
      <timepoint>3 YEARS</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of the occurrence of anti-AMG 386 antibody formation</outcome>
      <timepoint>3 YEARS</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects must have histologically or cytologically confirmed adenocarcinoma of the
             breast with locally recurrent or metastatic disease. Locally recurrent disease must
             not be amenable to resection with curative intent.

          -  Measurable or non-measurable disease per modified RECIST guidelines

          -  ECOG of 0 or 1 (within 14 days prior to randomization)

          -  Adequate organ and hematological function as evidenced by the following laboratory
             studies within 14 days prior to randomization:

              Cardiac function, as follows:

          -  Normal sinus rhythm (no significant ECG changes)

          -  Left ventricular ejection fraction = LLN, as determined by echocardiogram or MUGA
             scan, according to institutional standards within 28 days prior to randomization</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Inflammatory Breast Cancer

          -  Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 peripheral
             neuropathy &gt; grade 1 at randomization

          -  History of arterial or venous thrombosis, including transient ischemic attack (TIA),
             within 1 year prior to randomization

          -  Adjuvant or neoadjuvant taxane treatment within 12 months of randomization. Any other
             adjuvant chemotherapy regimen must be discontinued at least 21 days prior to
             randomization

          -  Prior chemotherapy, vaccine, or biological therapy for locally recurrent or metastatic
             breast cancer (prior endocrine therapy is permitted)

          -  Prior radiation therapy, radiofrequency ablation, percutaneous cryotherapy or hepatic
             chemoembolization on all sites of disease unless disease progression was subsequently
             documented 14 days prior to randomization.

          -  Overexpression of HER-2 (gene amplification by FISH or 3+ over expression by
             immunohistochemistry).

          -  Current or prior history of central nervous system metastasis

          -  History of bleeding diathesis or clinically significant bleeding within 6 months prior
             to randomization

          -  Major surgical procedure within 28 days prior to randomization

          -  Open breast biopsy within 14 days prior to randomization

          -  Minor surgical procedure, placement of access device, or fine needle aspiration within
             7 days of first dose

          -  Prior malignancy (other than thyroid cancer, in situ cervical cancer, or basal cell
             cancer of the skin, treated with curative intent and without evidence of disease for =
             3 years prior to randomization)

          -  Clinically significant cardiac disease within 12 months prior to randomization,
             including myocardial infarction, unstable angina, grade 2 or greater peripheral
             vascular disease, cerebrovascular accident, transient ischemic attack, congestive
             heart failure, or arrhythmias not controlled by outpatient medication

          -  Non-healing wound, ulcer or fracture

          -  Known hypersensitivity to paclitaxel or drugs using the vehicle cremophor

          -  Known hypersensitivity to bacterial proteins, or any of the drugs required in this
             study

          -  Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis
             B surface antigen

          -  Known active or chronic hepatitis

          -  Uncontrolled hypertension as defined as systolic blood pressure = 150 mm Hg and
             diastolic blood pressure = 90 mm Hg. Anti-hypertensive medications are allowed if the
             subject is stable on their current dose at the time of randomization

          -  Currently or previously treated with any VEGF or VEGFr inhibitor, including but not
             limited to, bevacizumab, SU11248 (sunitinib), PTK787 (vatalinib), AZD 2171, AEE-788,
             BAY 43-9006 (sorafenib) and AMG 706.

          -  Treatment with coumarin-type anticoagulants, (other than low dose prophylaxis for
             central venous catheters = 1mg/day) within 7 days prior to randomization

          -  Currently or previously treated with angiopoietin inhibitors, or inhibitors of TIE-1
             or TIE-2 including, but not limited to, AMG 386, XL880, XL820

          -  Treatment with immune modulators such as cyclosporine and tacrolimus within 30 days
             prior to randomization

          -  Concomitant therapy with any hormonal agent such as raloxifene, tamoxifen, or other
             selective estrogen receptor modulators (SERMS), given for breast cancer prevention or
             for osteoporosis. Subjects must have discontinued these agents 28 days prior to
             randomization

          -  Pregnant (ie, positive beta-human chorionic gonadotropin test) or is breast feeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>228</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>Research Site - Kurralta Park</hospital>
    <hospital>Research Site - Epping</hospital>
    <hospital>Research Site - Fitzroy</hospital>
    <hospital>Research Site - Footscray</hospital>
    <hospital>Research Site - Malvern</hospital>
    <hospital>Research Site - Perth</hospital>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>3076 - Epping</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Wilrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herlev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Roche Sur Yon Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier Cedex 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 20</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kaposvar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szombathely</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Veszprem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Rajasthan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lubin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>AndalucÃ-a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>CataluÃ±a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Galicia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Guildford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northwood</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase 2, randomized, placebo controlled, multi-center study to estimate the
      treatment effect and evaluate the safety and tolerability of AMG 386 in combination with
      paclitaxel and paclitaxel/bevacizumab in the treatment of subjects with Her2-negative
      metastatic or locally recurrent breast cancer.

      AMG 386 is a man-made medication that is designed to stop the development of blood vessels in
      cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called
      angiogenesis, to obtain a supply of oxygen and nutrients to grow.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00511459</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>